Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-20T20:20:48.808Z Has data issue: false hasContentIssue false
  • English
  • Français

Is High Consumption of Antibiotics Associated with Clostridium difficile Polymerase Chain Reaction–Ribotype 027 Infections in France?

Published online by Cambridge University Press:  02 January 2015

Gabriel Birgand ,
Katiuska Miliani ,
Anne Carbonne  and
Pascal Astagneau
Gabriel Birgand
Affiliation:
Regional Coordinating Center for Nosocomial Infection Control, Paris, France
Katiuska Miliani
Affiliation:
Regional Coordinating Center for Nosocomial Infection Control, Paris, France
Anne Carbonne
Affiliation:
Regional Coordinating Center for Nosocomial Infection Control, Paris, France
Pascal Astagneau*
Affiliation:
Regional Coordinating Center for Nosocomial Infection Control, Paris, France Department of Epidemiology and Public Health, Pierre et Marie Curie University School of Medicine, Paris, France
*
C-CLIN Paris Nord, Centre des Cordeliers, Université Pierre et Marie Curie, 15 Rue de l'Ecole de Médecine, 75006 Paris, France (p.astagne@bhdc.jussieu.fr).
Get access Rights & Permissions [Opens in a new window]

Extract

We compared antibiotic consumption between hospitals affected by a strain of Clostridium difficile designated as polymerase chain reaction–ribotype 027 (CD-027) and those unaffected during an outbreak in northern France. The mean consumption of several β-lactams, amikacin, and fluoroquinolones was high in affected hospitals (P<.05). However, only levofloxacin and imipenem remained associated with emerging CD-027 in the multivariate analysis, suggesting that those antibiotics should be better targeted by prevention campaigns.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue 3 , March 2010 , pp. 302 - 305
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kuijper, EJ, Coignard, B, Tull, P. Emergence of Clostridium difficile–associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):2–18.CrossRefGoogle ScholarPubMed
2.Owens, RC JrDonskey, CJ, Gaynes, RP, et al.Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S19–S31.CrossRefGoogle ScholarPubMed
3.Pepin, J, Saheb, N, Coulombe, MA, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.Google Scholar
4.Loo, VG, Poirier, L, Miller, MA, et al.A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.CrossRefGoogle ScholarPubMed
5.Pepin, J, Valiquette, L, Cossette, B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037–1042.CrossRefGoogle ScholarPubMed
6.Tachon, M, Cattoen, C, Blanckaert, K, et al.First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Euro Surveill 2006;11:E060504.Google ScholarPubMed
7.Miliani, K, L'Heriteau, F, Alfandari, S, et al.Specific control measures for antibiotic prescription are related to lower consumption in hospitals: results from a French multicentre pilot study. J Antimicrob Chemother 2008;62:823–829.CrossRefGoogle ScholarPubMed
8. Ministère de la Santé et des Sports. Tableau de Bord des Infections Nosocomials [in French]. 2008. Available at: http://www.icalin.sante.gouv.fr/. Accessed January 13, 2010.Google Scholar
9.Carlet, J, Astagneau, P, Brun-Buisson, C, et al.French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol 2009;30:737–745.Google Scholar
10.Baxter, R, Ray, GT, Fireman, BH. Case-control study of antibiotic use and subsequent Clostridium difficile–associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44–50.Google Scholar
11.Warny, M, Pepin, J, Fang, A, et al.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079–1084.CrossRefGoogle ScholarPubMed
12.Muto, CA, Pokrywka, M, Shutt, K, et al.A large outbreak of Clostridium difficile–associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273–280.Google Scholar
13.Biller, P, Shank, B, Lind, L, et al.Moxifloxacin therapy as a risk factor for Clostridium difficile–associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198–201.CrossRefGoogle ScholarPubMed